Flanvotumab, also known as ''IMC-20D7S'', is a human monoclonal antibody designed for the treatment of melanoma.
It targets TYRP1.
Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.
References
Monoclonal antibodies
Abandoned drugs
{{antineoplastic-drug-stub